<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83338">
  <stage>Registered</stage>
  <submitdate>7/11/2008</submitdate>
  <approvaldate>21/01/2009</approvaldate>
  <actrnumber>ACTRN12609000048280</actrnumber>
  <trial_identification>
    <studytitle>A phase III study comparing Sorafenib with placebo in patients who have had kidney cancer removed (SORCE)</studytitle>
    <scientifictitle>A phase III randomised double-blind study comparing Sorafenib with placebo in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse.</scientifictitle>
    <utrn />
    <trialacronym>SORCE</trialacronym>
    <secondaryid>NCT00492258</secondaryid>
    <secondaryid>ISRCTN38934710 </secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention group 1 and group 2 will self administer 400 mg of sorafenib (2 x 200 mg tablets) and Intervention group 3 will self-administer matching placebo tablets once per day for 21 days. At 21 days the dose will be increased to 400 mg (2 x 200mg tablets) or matching placebo twice per day if the patient has not experienced greater than Grade I skin toxicity or greater than Grade II of any other toxicity. Dose escalation may be deferred until at least the planned 6 week visit if toxicities do occur. After the first 21 days Intervention group 1 and group 2 will receive sorafenib at 400mg oral dose (2 x 200mg tablets) twice daily until the end of the first year, followed by Placebo (2 x oral sugar pills twice daily for 2 years). Intervention group 2 will receive sorafenib at 400mg oral dose (2 x 200mg tablets) twice daily until the completion of the three years. The tablets should be swallowed whole with a glass of water. The tablets should be taken without food (at least 1 hour before or 2 hours after eating) or with a moderate fat meal. Twice daily doses should be separated by approximately 12 hours.</interventions>
    <comparator>The comparator/control gorup will receive placebo (2 x oral sugar pills twice daily for 3 years).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free survival, measured by 6-monthly computer tomography (CT) of chest, abomen and pelvis, with 6-monthly chest x-rays in-between.</outcome>
      <timepoint>Baseline, 3 weeks, 6 weeks and 3 months post-randomisation, then 3-monthly until 3 years post-randomisation.  6-monthly chest x-rays only between 3 and 6 years post-randomisation.  Yearly chest x-rays only following first 5 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Renal cell carcinoma (RCC)-specific survival time</outcome>
      <timepoint>Baseline, 3 weeks, 6 weeks and 3 months post-randomisation, then 3-monthly until 5 years post-randomisation.  Yearly following first 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>overall survival</outcome>
      <timepoint>Clinical examination follow-up of patients at 3 weeks, 6 weeks and 3 months post-randomisation, then 3-monthly until 3 years post-randomisation.  6-monthly between 3 and 6 years post-randomisation.  Yearly following first 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicities will be measured using Cancer Toxicity Criteria for Adverse Events (CTCAE) version 3.0.</outcome>
      <timepoint>Baseline, 3 weeks, 6 weeks and 3 months post-randomisation, then 3-monthly until 5 years post-randomisation.  Yearly following first 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>biological characteristics of resected primary RCC (ie the Von Hippel Lindau (VHL) gene, the vascular endothelial growth factor receptor 2 (VEGFR2) gene, fibroblast growth factor 2 (FGF2), B-RAF, MEK, ERK).</outcome>
      <timepoint>Measured from tissue collected at time of surgery and blood collected at time of randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Leibovich Calculated Score for risk of relapse in renal cell carcinoma</outcome>
      <timepoint>At time of surgery.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria: Histologically proven renal cell carcinoma. No evidence of residual macroscopic disease on post-operative Computerised Tomography (CT) scan after resection of renal cell carcinoma. Patients with clear cell or non-clear cell tumours are eligible. Patients with "intermediate" or "high" risk per the Leibovich score 3 to 11. Subjects must be &gt;18 years in age. Women of childbearing age must have a negative pregnancy test and must use adequate contraception during the treatment phase of hte study and for 9 months afterwards. Women who wish to breast feed are not eligible for the study. Adequate bone marrow function (White Blood Cell (WBC) &gt; 3.4 x 109/L, platelets &gt; 99 x 109/L) renal function (creatinine &lt; 2.5 x the Upper Limit of Normal (ULN)) and hepatic function (Liver Function Test (LFT) &lt; 1.5 x ULN) within 14 days prior to randomisation. Patients should have had surgery at least 4 weeks but no more than 3 months (91d) prior to treatment start date. Serum amylase &lt; 1.5 x ULN Prothrombin or International Normalised Ratio (INR) and prothrombin time &lt; 1.5 x ULN World Health Organisation (WHO) performance status 0 or 1. Written informed consent obtained.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prior anti-cancer treatment for renal cell carcinoma other than nephrectomy Cardiac arrhythmias requiring anti-arrhythmics (beta blockers and digoxin are allowed), symptomatic coronary artery disease or ischaemia, myocardial infarction within the last 6 months, congestive cardiac failure &gt; (New York Heart Association (NYHA) class II. Active clinically serious bacterial or fungal infections. Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C. Pregnant or breast-feeding patients. Prior malignancy (except for cervical carcinoma in situ or adequately treated basal cell carcinoma). Concomitant medications which have adverse interactions with sorafenib: rifampin, grapefruit juice, ritonavir, ketoconazole, itraconazole and St John's Wort. Patients with uncontrolled hypertension.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/2009</anticipatedstartdate>
    <actualstartdate>1/06/2007</actualstartdate>
    <anticipatedenddate>1/06/2012</anticipatedenddate>
    <actualenddate>12/04/2013</actualenddate>
    <samplesize>1656</samplesize>
    <actualsamplesize>1711</actualsamplesize>
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,ACT,QLD,SA,WA,TAS</recruitmentstate>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Medical Research Council</primarysponsorname>
    <primarysponsoraddress>222 Euston Road
London
NW1 2DA</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Clinical Trials Advisory and Awards Committee (CTAAC): Cancer Research UK</fundingname>
      <fundingaddress>Cancer Research UK
61 Lincoln's Inn Fields
London
WC2A 3PX</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer AG</fundingname>
      <fundingaddress>Bayer AG
51368 Leverkusen</fundingaddress>
      <fundingcountry>Germany</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)</fundingname>
      <fundingaddress>Lifehouse, Level 6, 119-143 Missenden Road, Camperdown NSW 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Sydney</sponsorname>
      <sponsoraddress>NHMRC Clinical Trials Centre 
Level 6, Medical Foundations Building, 92-94 Parramatta Road Camperdown NSW 2050</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study looks at the effectiveness the drug Sorafenib on treating patients who have had kidney cancer removed surgically. 


Who is it for?
You can join this study if you have had primary renal cell carcinoma and this has been removed by surgery, and you are at high or intermediate risk of relapse.


Trial details
Participants will be randomly divided into three groups. Group 1 will receive a non-active substance (placebo) for 3 years. Group 2 will receive Sorafenib for 1 year followed by placebo for 2 years. Group 3 will receive Sorafenib only for 3 years. Treatment is by tablets taken twice a day.

At the moment there are no treatments that have been proven to reduce the risk of kidney cancer returning after it has been removed by an operation. Sorafenib is a drug that acts starving cancers of their blood supply and will often shrink or stop cancer growing for prolonged periods of time. The study aims to see whether Sorafineb reduces the risk of kidney cancer returning and whether it increases survival rate.</summary>
    <trialwebsite>www.anzup.org.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney Local Health District Ethics Review Committee (RPAH zone) </ethicname>
      <ethicaddress>Research Development Office
Royal Prince Alfred Hospital
Missenden Road
CAMPERDOWN NSW 2050 </ethicaddress>
      <ethicapprovaldate>5/11/2008</ethicapprovaldate>
      <hrec>AU RED Reference Number: 08/CIC/26
Cancer Institute NSW Reference Number: 2008C/08/060</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>ACT Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Building 10
Level 6
Canberra Hospital
Garran ACT 2605</ethicaddress>
      <ethicapprovaldate>11/05/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Alfred Hospital Ethics Committee </ethicname>
      <ethicaddress>OFFICE OF ETHICS &amp; RESEARCH GOVERNANCE 
Ground Floor 
Linay Pavilion 
The Alfred
Prahran VIC 3181 </ethicaddress>
      <ethicapprovaldate>21/05/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Eastern Health Human Research Ehics Committee</ethicname>
      <ethicaddress>Level 2
5 Arnold Street
Box Hill VIC 3128</ethicaddress>
      <ethicapprovaldate>1/07/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>145 Studley Road
Heidelberg
VIC 3084
</ethicaddress>
      <ethicapprovaldate>17/10/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bellberry Limited Human Research Ethics Committee</ethicname>
      <ethicaddress>129 Glen Osmond Road 
Eastwood 
SA 5063 
</ethicaddress>
      <ethicapprovaldate>30/11/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Royal Brisbane &amp; Womenâ€™s Hospital Human Research Ethics Committee </ethicname>
      <ethicaddress>Level 7, Block 7
Royal Brisbane and Women's Hospital
Metro North Health Service District
Herston
QLD 4006</ethicaddress>
      <ethicapprovaldate>29/06/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 3
Hanson Institute
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>5/10/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Southern Adelaide Clinical Human Research Ethics Committee </ethicname>
      <ethicaddress>Flinders Medical Centre
Bedford Park 
SA 5042
</ethicaddress>
      <ethicapprovaldate>5/11/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Giardner Group Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 2 A Block
Hospital Ave
Nedlands
WA 6009</ethicaddress>
      <ethicapprovaldate>14/07/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>South Metropolitam Area Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 2, Southern Research Facility (Perkins Building) 
Fiona Stanley Hospital
11 Robin Warren Drive
MURDOCH WA 6150
</ethicaddress>
      <ethicapprovaldate>3/06/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname> Human Research Ethics Committee of Tasmania </ethicname>
      <ethicaddress>Office of Research Services, University of Tasmania, Private Bag 1, Hobart, TAS, 7001</ethicaddress>
      <ethicapprovaldate>13/08/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>SORCE Trial Coordinator</name>
      <address>NHMRC Clinical Trials Centre 
The Lifehouse Building
Level 6
119 -143 Missenden Road
Camperdown NSW 2050</address>
      <phone>(02) 9562 5000</phone>
      <fax>(02) 9562 5094</fax>
      <email>sorce@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>SORCE Trial Coordinator</name>
      <address>NHMRC Clinical Trials Centre 
The Lifehouse Building
Level 6
119 -143 Missenden Road
Camperdown NSW 2050
</address>
      <phone>(02) 9562 5000</phone>
      <fax>(02) 9562 5094</fax>
      <email>sorce@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>SORCE Trial Coordinator</name>
      <address>NHMRC Clinical Trials Centre 
The Lifehouse Building
Level 6
119 -143 Missenden Road
Camperdown NSW 2050</address>
      <phone>(02) 9562 5000</phone>
      <fax>(02) 9562 5094</fax>
      <email>sorce@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ian Davis</name>
      <address>Eastern Health Clinical School
Faculty of Medicine, Nursing and Health Sciences
Level 2, 5 Arnold St
Box Hill
Vic 3128
Australia</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>sorce@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>